Physician profile
James Richards
NPI 1235227778
$5,606.61
in general payments reported to CMS, 2019-2025
26 companies · $877 in 2025
The $877 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,352 · 2020: $464 · 2021: $545 · 2022: $834 · 2023: $847 · 2024: $689 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,380 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,380.09 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,382.78 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $953.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $840.41 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $311.21 | 2019-2023 | |
| Glaxosmithkline, LLC. | $221.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.77 | 2019-2023 | Jardiance |
| Janssen Biotech, INC. | $178.46 | 2019-2024 | Darzalex, Tecvayli |
| Amgen INC. | $147.81 | 2025 | Krystexxa, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $134.19 | 2019-2024 | Xarelto |
| Pfizer INC. | $134.19 | 2019-2024 | |
| Genentech USA, INC. | $122.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $120.64 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $119.48 | 2021 | |
| Kyowa Kirin, INC. | $116.33 | 2025 | |
| Amarin Pharma, INC. | $106.76 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $100.78 | 2025 | Bimzelx |
| Exact Sciences Corporation | $88.63 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $70.06 | 2022-2023 | Freestyle Libre 3 |
| Shield Therapeutics INC | $67.90 | 2022-2023 | Accrufer |
| Eisai INC. | $63.19 | 2019 | |
| Gilead Sciences, INC. | $28.94 | 2025 | |
| Ascensia Diabetes Care US INC. | $28.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.78 | 2022 | |
| Alk-Abello, INC | $20.65 | 2024 | Grastek, Odactra, Ragwitek |
| Horizon Therapeutics Plc | $19.27 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $18.34 | 2023 | Prehevbrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.